{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269518","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.575418+00:00","generated_at":"2026-05-16T23:56:52.968556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues","bullets":["Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.","Cash, equivalents & short-term investments totaled $989.0M, down from $1.03B at Dec 31, 2024.","Enrollment ongoing in Phase 1 trials for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected Q4 2025.","G&A expense fell to $10.6M vs $17.7M, last year included $9.5M stock-comp modification charge."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269518","json":"https://secwatch.observer/filing/0001193125-25-269518.json","markdown":"https://secwatch.observer/filing/0001193125-25-269518.md","text":"https://secwatch.observer/filing/0001193125-25-269518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/0001193125-25-269518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/janx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:56:52.968556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}